918 / 1542
Trial Design
•
This trial was undertaken to test the benefit of adding the hypoxic cell
cytotoxin tirapazamine (TPZ) to cisplatin (CIS) -based chemoradiotherapy
in patients with locoregionally advanced squamous cell carcinoma of the
head and neck
•
Radiotherapy
•
RT in both arms
•
70 Gy in 35 fractions in 7 weeks to gross disease
•
50 Gy in 25 fractions in 5 weeks to electively treated areas
•
Chemotherapy
•
Arm A: Cisplatin
•
Arm B: Cisplatin + Tirapazamine
•
Powered at 90% to detect 10% improvement in survival at two years
Lester J. Peters, Brian O'Sullivan, Jordi Giralt, Thomas J. Fitzgerald, Andy Trotti, Jacques Bernier,
Jean Bourhis, Kally Yuen, Richard Fisher and Danny Rischin. JCO 2010;28:2996-3001.